利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

132 条记录 (耗时 0.059 秒)

    Methods of using Bcl-2 for the therapeutic treatment and prevention of diseases
    51.
    发明授权
    Methods of using Bcl-2 for the therapeutic treatment and prevention of diseases 失效
    使用Bcl-2治疗和预防疾病的方法

    公开(公告)号：US07427495B2

    公开(公告)日：2008-09-23

    申请号：US10285853

    申请日：2002-11-01

    申请人： John C. Reed

    发明人： John C. Reed

    IPC分类号： C12P21/08 ,  C12N5/20 ,  C12N5/24

    CPC分类号： A01K67/0275 ,  A01K67/0271 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/025 ,  A01K2267/03 ,  A01K2267/0318 ,  A61K35/39 ,  A61K38/00 ,  C07K14/82 ,  C07K16/00 ,  C12N15/8509 ,  C12N2840/20 ,  C12N2840/203

    摘要： The invention provides a method of treating a disease or pathological condition resulting in apoptotic cell death. The method includes increasing the activity of Bcl-2 in cells affected by the disease or pathological condition. Diseases or pathological conditions can include, for example, neurodegenerative diseases, cancer and viral infections. Also provided is a method of prolonging the in vivo survival of transplanted cells for the treatment of a disease or pathological condition. The method includes increasing the activity of Bcl-2 in a population of cells and transplanting the population of cells having increased Bcl-2 activity into a subject. Diseases or pathological conditions can include, for example, neurodegenerative diseases, cancer and viral infections. A method to enhance the sensitivity of malignant cells to therapy is provided that includes decreasing the activity of Bcl-2 in the malignant cells. Methods to identify compounds that alter apoptotic cell death and to enhance monoclonal antibody production are also provided by the invention disclosed herein.

    摘要翻译： 本发明提供了治疗导致凋亡性细胞死亡的疾病或病理状况的方法。 该方法包括增加Bcl-2在受疾病或病理状况影响的细胞中的活性。 疾病或病理状况可包括例如神经变性疾病，癌症和病毒感染。 还提供了延长移植细胞的体内存活以治疗疾病或病理状况的方法。 该方法包括增加细胞群中Bcl-2的活性，并将具有增加的Bcl-2活性的细胞群体移植到受试者中。 疾病或病理状况可包括例如神经变性疾病，癌症和病毒感染。 提供了增强恶性细胞对治疗的敏感性的方法，其包括降低恶性细胞中Bcl-2的活性。 鉴定化合物的方法来鉴定改变凋亡细胞死亡和增强单克隆抗体产生的化合物也由本文公开的本发明提供。

    METHOD FOR DETERMINING THE PROGNOSIS OF CANCER PATIENTS BY MEASURING LEVELS OF BAG EXPRESSION
    53.
    发明申请
    METHOD FOR DETERMINING THE PROGNOSIS OF CANCER PATIENTS BY MEASURING LEVELS OF BAG EXPRESSION 审中-公开
    通过测量囊表达水平来确定癌症患者预后的方法

    公开(公告)号：US20080166733A1

    公开(公告)日：2008-07-10

    申请号：US12052693

    申请日：2008-03-20

    申请人： John C. Reed

    发明人： John C. Reed

    IPC分类号： C12Q1/68 ,  C12Q1/00 ,  G01N33/483

    CPC分类号： G01N33/57407 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N2800/52

    摘要： In accordance with the present invention, there are provided methods for determining a prognosis of disease free or overall survival in a patient suffering from cancer. Also provided are methods for predicting the risk of tumor recurrence or spread in an individual having a cancer tumor. Methods for screening a cancer patient to determine the risk of tumor metastasis; methods for determining the proper course of treatment for a patient suffering from cancer; and kits for use in practicing the invention methods.

    摘要翻译： 根据本发明，提供了确定患有癌症的患者中无疾病或总体存活的预后的方法。 还提供了用于预测具有癌肿瘤的个体中肿瘤复发或扩散的风险的方法。 筛选癌症患者以确定肿瘤转移风险的方法; 确定患有癌症的患者的适当治疗过程的方法; 以及用于实施本发明方法的试剂盒。

    Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto
    54.
    发明授权
    Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto 失效
    涉及蛋白质降解的核酸编码蛋白质，与其有关的产品和方法

    公开(公告)号：US07390656B2

    公开(公告)日：2008-06-24

    申请号：US11441861

    申请日：2006-05-26

    申请人： John C. Reed ,  Shu-ichi Matsuzawa

    发明人： John C. Reed ,  Shu-ichi Matsuzawa

    IPC分类号： C12N5/00 ,  C07H21/02

    CPC分类号： C07K14/47 ,  C07K14/00 ,  Y10T436/143333

    摘要： In accordance with the present invention, there are provided novel Siah-Mediated-Degradation-Proteins (SMDPs) and/or SCF-Complex Proteins (SCPs). Nucleic acid sequences encoding such proteins and assays employing same are also disclosed. The invention SMDPs and/or SCPs can be employed in a variety of ways, for example, for the production of anti-SMDP and/or SCP antibodies thereto, in therapeutic compositions, and methods employing such proteins and/or antibodies for drug screening, functional genomics and other applications. Also provided are transgenic non-human mammals that express the invention protein.

    摘要翻译： 根据本发明，提供了新型的Siah介导的降解蛋白（SMDP）和/或SCF-复合蛋白（SCP）。 还公开了编码这种蛋白质的核酸序列和使用其的测定法。 本发明SMDP和/或SCP可以以各种方式使用，例如用于在治疗组合物中生产抗SMDP和/或SCP抗体，以及使用这种蛋白质和/或抗体用于药物筛选的方法， 功能基因组学等应用。 还提供了表达本发明蛋白质的转基因非人哺乳动物。

    Digital beam forming for communications systems
    55.
    发明授权
    Digital beam forming for communications systems 有权
    通信系统的数字波束形成

    公开(公告)号：US07373127B2

    公开(公告)日：2008-05-13

    申请号：US11115721

    申请日：2005-04-27

    申请人： John C. Reed

    发明人： John C. Reed

    IPC分类号： H04B1/06

    CPC分类号： H04B7/086 ,  H04B7/0845 ,  H04B7/088

    摘要： An antenna-receiver communications system and method is provided to mechanize multibeam mobile antenna-receive subsystems. Digital beam forming for modern wideband mobile communications systems is provided. In an aspect, subsystems can simultaneously receive, acquire, track and output a multiplicity of signals from sources of different locations using a single antenna aperture from a mobile platform. The angle of arrival of a signal of interest is continuously determined. Individual phased array antenna output channels are phased aligned as required by the phased array equation and monopulse signal processing. Angle sensing and beamsteering are separated from antenna channel coherent summation. Thus, the angle sensing and beamsteering functions are not required to be computed at the data rate, but can instead be computed at a rate necessary for the beam acquisition and beam tracking function speed requirements. Signal processing computational load and system cost is reduced as compared to current systems.

    摘要翻译： 提供天线接收机通信系统和方法来机械化多波束移动天线接收子系统。 提供了现代宽带移动通信系统的数字波束形成。 在一个方面，子系统可以使用来自移动平台的单个天线孔，同时从不同位置的来源接收，获取，跟踪和输出多个信号。 连续确定感兴趣信号的到达角度。 单相相控阵天线输出通道根据相控阵方程和单脉冲信号处理的要求进行相位对准。 角度感测和波束导向与天线信道相干相加分离。 因此，角度感测和波束导向功能不需要以数据速率计算，而是可以以波束采集和波束跟踪功能速度要求所需的速率来计算。 与现有系统相比，信号处理计算负荷和系统成本降低。

    TRAF family proteins
    56.
    发明授权
    TRAF family proteins 失效
    TRAF家族蛋白

    公开(公告)号：US07208581B1

    公开(公告)日：2007-04-24

    申请号：US09706325

    申请日：2000-11-03

    申请人： Juan M. Zapata ,  John C. Reed

    发明人： Juan M. Zapata ,  John C. Reed

    IPC分类号： C07K16/00 ,  C12P21/08 ,  C12N5/06

    CPC分类号： C07K16/18

    摘要： In accordance with the present invention, there are provided novel TRAF-Protein-Binding-Domain polypeptides (TPBDs). The invention also provides nucleic acid molecules encoding TPBDs, vectors containing these nucleic acid molecules and host cells containing the vectors. The invention also provides antibodies that can specifically bind to invention TPBDs. Such TPBDs and/or anti-TPBD antibodies are useful for discovery of drugs that suppress autoimmunity, inflammation, allergy, allograph rejection, sepsis, and other diseases.

    摘要翻译： 根据本发明，提供了新型TRAF-蛋白结合域多肽（TPBD）。 本发明还提供编码TPBD的核酸分子，含有这些核酸分子的载体和含有载体的宿主细胞。 本发明还提供可以特异性结合本发明的TPBD的抗体。 这样的TPBD和/或抗TPBD抗体可用于发现抑制自身免疫，炎症，过敏，同种异体排斥，败血症和其它疾病的药物。

    Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity
    60.
    发明授权
    Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity 失效
    用于改变caspase活性的凋亡抑制剂（IAP）蛋白调节剂的筛选试验

    公开(公告)号：US06228603B1

    公开(公告)日：2001-05-08

    申请号：US09058969

    申请日：1998-04-10

    申请人： John C. Reed ,  Quinn Deveraux ,  Guy S. Salvesen ,  Ryosuke Takahashi ,  Natalie Roy

    发明人： John C. Reed ,  Quinn Deveraux ,  Guy S. Salvesen ,  Ryosuke Takahashi ,  Natalie Roy

    IPC分类号： G01N3353

    CPC分类号： G01N33/5011 ,  C12Q1/37 ,  G01N33/573 ,  G01N2333/96466 ,  G01N2500/00 ,  G01N2500/10 ,  G01N2510/00

    摘要： The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7. The invention also provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a pro-caspase such as pro-caspase-9. In addition, the invention also provides methods for identifying agents that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP. The invention further provides methods of reducing the severity of a pathologic condition in an individual by administering to the individual an agent that alters the caspase inhibitory activity of an IAP. In addition, the invention provides methods of modulating the ability of a population of cells to survive ex vivo by contacting the cells with an agent that alters the caspase inhibitory activity of an IAP in the cells.

    摘要翻译： 本发明涉及凋亡抑制剂（IAP）蛋白和细胞死亡蛋白酶半胱天冬酶家族的成员之间的作用，例如，X染色体连接的IAP（XIAP）和半胱天冬酶-3的相互作用，半胱天冬酶-7或 胱天蛋白酶-9，其中IAP调节胱天蛋白酶的活性。 本发明提供用于鉴定改变IAP（诸如XIAP，c-IAP-1或c-IAP-2）和半胱天冬酶（例如半胱天冬酶-3或半胱天冬酶-7）的IAP的特异性缔合的试剂的筛选试验。 本发明还提供用于鉴定改变IAP如XIAP，c-IAP-1或c-IAP-2和前半胱天冬酶如前半胱天冬酶-9的特异性关联的试剂的筛选试验。 此外，本发明还提供了鉴定在IAP存在下调节半胱天冬酶的活性并且通过IAP调节前半胱天冬酶的活化的试剂的方法。 本发明还提供了通过向个体施用改变IAP的半胱天冬酶抑制活性的试剂来降低个体病理状况的严重性的方法。 此外，本发明提供了通过使细胞与改变细胞中IAP的半胱天冬酶抑制活性的试剂接触来调节细胞群体离体存活的能力的方法。